Sirolimus and paxlitaxel eluting stents yield similar clinical outcomes when used for selected high risk indications only: results from a large Australian registry

R. Gurvitch,R. J. Warren,J. Lefkovits,D. Eccleston,S. J. Duffy, D. J. Clark,A. Brennan, N. Andrionopoulos,A. E. Ajani

Heart, Lung and Circulation（2008）

引用 0|浏览4

暂无评分

摘要

Background: Drug eluting stent (DES) trials have excluded patients with high-risk lesion characteristics. We aimed to assess whether sirolimus- or paclitaxel-eluting stents (SES and PES) are best for high-risk indications in a “real world” contemporary interventional practise.

查看译文

关键词

stents,high risk indications,clinical outcomes,similar clinical outcomes,paxlitaxel-eluting

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要